Institute of Biomedical Research (OTC: MRES) (doing business as M2Bio Sciences) is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence and evidence-based sustainable products and solutions. M2Bio Sciences today announced the forthcoming launch of a captivating line of teas sourced from the scenic gardens of Kenya. The meticulously crafted collection provides not only an exquisite sensory experience but also delivers exceptional medicinal health benefits. “We are delighted to introduce our exceptional line of purple, white and green teas from Kenya,” said Jeff Robinson, CEO of M2Bio Sciences. “Our purple tea strain has about 135 times more antioxidants* compared to a traditional black tea, so we definitely tick the box for health. In terms of addressable market, according to a report published by Vantage Market Research, the global green tea market was valued at US$13.41 billion in 2021 and is projected to reach US$26.16 billion by 2028 with a CAGR of 8.71%**. We plan to take a good chunk of that! These teas embody our commitment to providing products that promote holistic well-being. Through our partnership with the esteemed tea experts of Kenya and our team of researchers in the M2Bio Phytomedicine Labs at the University of Pretoria, we are able to offer tea enthusiasts worldwide an unparalleled combination of extraordinary taste and outstanding health benefits.”
To view the full press release, visit https://ibn.fm/1DjKX
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions, that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx(TM), Medspresso(TM), Liviana(TM) brands as well as artificial intelligence powered nutrition products and solutions under the M2Biome brand. In addition, its research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. The company’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies such as artificial intelligence. The company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol MRES. For more information, visit the company’s website at www.M2Bio.co.
*Khan et al., Med Aromat Plants (Los Angeles) Purple Tea Composition and Inhibitory Effect of Anthocyanin-Rich Extract on Cancer Cell Proliferation 2018, 7:6 DOI: 10.4172/2167-0412.1000322 https://www.semanticscholar.org/paper/Purple-tea-composition-and-inhibitory-effect-of-on-Khan-Bashir/b214419bc08ee495790648719dd5d40026932fe2
**Vantage Market Research Green-Tea-Market-Size-Share-to-Surpass-26-16-Billion-by-2028-Vantage-Market-Research
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
